Equities

Industri Jamu dan Farmasi Sido Muncul Tbk PT

SIDO:JKT

Industri Jamu dan Farmasi Sido Muncul Tbk PT

Actions
Consumer Staples Food Producers
  • Price (IDR)710.00
  • Today's Change10.00 / 1.43%
  • Shares traded59.80m
  • 1 Year change-2.07%
  • Beta0.2484
Data delayed at least 10 minutes, as of May 31 2024 10:13 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Industri Jamu Dan Farmasi Sido Muncul Tbk is an Indonesia-based company, which carries out business activities in herbal industry, such as medical industry (pharmacy), herbs, cosmetics, foods and beverages related to health, commerce, land transportation, services, wastewater treatment, plantation and printing. The Company's segments include Herbal medicine and supplement, Food and beverages and Pharmacy. The Company’s products include Tolak Angin Cair, Tolak Angin Anak + Madu, Tolak Angin Flu, Tolak Angin Sugar Free, Sido Muncul Tolak Linu, Kuku Bima Ener-G!, Susu Jahe, Kopi Jahe, Sido Muncul C-1000 (Dengan Ekstrak Lemon), Esemag, Sari Kunyit Soft Capsule, Tolak Angin Soft Capsule, Tolak Linu Soft Capsule, JSH Capsule, VCO Soft Capsule, Sido Muncul Vitamin D3 400 IU, Sido Muncul VItamin E 100 IU, Sido Muncul Vitamin E 300 IU, Minuman Madu dengan Jahe MADUSIDO, Tolak Angin Care, Tolak Linu Cool, Anak Sehat Rasa Anggur, Anak Sehat Rasa Coklat, and Anak Sehat Rasa Jambu Merah.

  • Revenue in IDR (TTM)3.71tn
  • Net income in IDR1.04tn
  • Incorporated1981
  • Employees3.48k
  • Location
    Industri Jamu dan Farmasi Sido Muncul Tbk PTGedung Menara Suara Merdeka 16th FloorJl. Pandanaran No. 30SEMARANG 50134IndonesiaIDN
  • Phone+62 2 476928811
  • Fax+62 2 476928815
  • Websitehttps://www.sidomuncul.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Animal Husbandry Industry Co., Ltd12.27tn760.87bn20.10tn4.33k26.411.60--1.640.33210.33215.365.480.63314.134.891,264,384.003.336.234.719.0118.9524.295.268.691.86--0.201731.20-8.244.04-26.73-0.612724.20-3.77
Shenzhen Chipscreen Biosciences Co Ltd1.23tn231.15bn20.24tn1.06k85.815.34--16.470.25780.25781.334.150.17611.663.97518,248.702.141.322.611.5486.9993.2912.176.972.99--0.40370.00-1.1828.81408.0923.3110.23--
Nanjing Vazyme Biotech Co Ltd2.88tn-33.92bn20.65tn2.70k--2.28--7.16-0.0368-0.03683.2710.070.21910.97612.85476,061.10-0.28613.16-0.372415.9271.3170.50-1.3123.922.97--0.215432.20-63.9749.74-111.94--48.61--
Aurisco Pharmaceutical Co Ltd2.91tn730.91bn20.94tn1.52k28.614.49--7.200.8030.8033.185.120.54041.174.99852,082.9013.5712.4016.4614.3356.9051.2625.1223.051.72--0.11625.1525.2417.0237.2316.1626.54--
Zhejiang Hisun Pharmaceutical Co., Ltd.22.52tn-172.65bn20.95tn8.06k--1.13--0.9303-0.0823-0.08238.456.860.55353.324.531,244,871.00-0.50841.95-0.85693.7738.3540.58-0.91873.430.6303--0.415826.07-13.820.3618-119.05---31.58--
Luye Pharma Group Ltd13.80tn1.20tn20.95tn5.27k17.420.74427.521.520.15380.15381.783.600.2472.423.601,260,044.002.172.803.564.4568.4470.538.7810.391.213.100.393111.822.703.50-11.94-16.39-14.05--
Jubilant Pharmova Ltd13.05tn150.13bn21.22tn1.03k141.872.0123.971.634.854.85421.25343.160.59041.607.14--0.64042.960.76273.5568.0669.371.085.131.372.090.403324.696.70-5.95226.43-33.086.482.13
Shanghai Henlius Biotech Inc12.12tn1.23tn21.28tn3.64k17.404.3210.461.761.081.0810.684.360.57311.959.101,603,434.005.80-8.5912.47-14.1472.6471.7710.12-27.370.37866.480.6512--67.82273.51178.53--49.14--
Industri Jamu dn Frms Sd Mncl Tbk PT3.71tn1.04tn21.30tn3.48k20.465.6218.435.7434.7034.70123.74126.400.87623.424.661,076,581,000.0024.5726.4229.7830.3358.2155.9328.0428.334.9825.290.002395.34-7.755.23-13.957.45-27.1311.37
Zhejiang Medicine Co., Ltd.18.03tn955.33bn21.57tn6.23k22.280.9835--1.200.4470.4478.4110.130.63292.915.571,290,409.002.144.322.755.6831.1636.573.396.281.625.950.081958.72-3.962.59-20.373.3412.650.00
Data as of May 31 2024. Currency figures normalised to Industri Jamu dan Farmasi Sido Muncul Tbk PT's reporting currency: Indonesian Rupiah IDR

Institutional shareholders

3.12%Per cent of shares held by top holders
HolderShares% Held
eQ Varainhoito Oyas of 31 Jan 2024209.15m0.70%
The Vanguard Group, Inc.as of 09 May 2024201.15m0.67%
First Sentier Investors (UK) IM Ltd.as of 30 Apr 2024108.08m0.36%
Dimensional Fund Advisors LPas of 09 May 202494.19m0.31%
BlackRock Fund Advisorsas of 09 May 202490.53m0.30%
PT Schroder Investment Management Indonesiaas of 31 Dec 202368.67m0.23%
AllianceBernstein Ltd.as of 31 Mar 202456.45m0.19%
Mellon Investments Corp.as of 09 May 202444.23m0.15%
TIAA-CREF Investment Management LLCas of 31 Mar 202434.38m0.12%
Teachers Advisors LLCas of 31 Mar 202428.82m0.10%
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.